Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3

Highlights • CsA significantly augments the anti-cancer effect of gefitinib in NSCLC cells. • CsA promotes gefitinib-induced apoptosis through inhibition of the STAT3 pathway. • NSCLC patients with high p-STAT3 have poorer therapeutic response to EGFR-TKIs. • Combination of CsA with EGFR-TKIs is a p...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer letters 2016-08, Vol.379 (1), p.124-133
Hauptverfasser:	Shou, Jiawei, You, Liangkun, Yao, Junlin, Xie, Jiansheng, Jing, Jing, Jing, Zhao, Jiang, Liming, Sui, Xinbing, Pan, Hongming, Han, Weidong
Format:	Artikel
Sprache:	eng
Schlagworte:	A549 Cells Animals Antineoplastic Combined Chemotherapy Protocols - pharmacology Apoptosis Apoptosis - drug effects Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - metabolism Carcinoma, Non-Small-Cell Lung - pathology Cell cycle Chemotherapy Cyclosporine - pharmacology Cyclosporine A Dose-Response Relationship, Drug Drug Resistance, Neoplasm - drug effects EGFR–TKI Female Hematology, Oncology and Palliative Medicine Humans Kinases Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - metabolism Lung Neoplasms - pathology Lymphocytes Mice, Inbred BALB C Mice, Nude Mutation NFATC Transcription Factors - genetics NFATC Transcription Factors - metabolism Phosphorylation Plasmids Protein Kinase Inhibitors - pharmacology Quinazolines - pharmacology Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - metabolism Response rates RNA Interference Science Signal Transduction - drug effects STAT3 STAT3 Transcription Factor - antagonists & inhibitors STAT3 Transcription Factor - genetics STAT3 Transcription Factor - metabolism Studies Time Factors Transfection Transplants & implants Tumor Burden - drug effects Tumors Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • CsA significantly augments the anti-cancer effect of gefitinib in NSCLC cells. • CsA promotes gefitinib-induced apoptosis through inhibition of the STAT3 pathway. • NSCLC patients with high p-STAT3 have poorer therapeutic response to EGFR-TKIs. • Combination of CsA with EGFR-TKIs is a promising approach to treat NSCLC patients.
ISSN:	0304-3835 1872-7980
DOI:	10.1016/j.canlet.2016.06.002